Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial
Vivek Subbiah, Philippe A Cassier, Salvatore Siena, Elena Garralda, Luis Paz-Ares, Pilar Garrido, Ernest Nadal, Jacqueline Vuky, Gilberto Lopes, Gregory P Kalemkerian, Daniel W Bowles, Mahesh Seetharam, Jianhua Chang, Hui Zhang, Jennifer Green, Alena Zalutskaya, Martin Schuler, Yun Fan, Giuseppe Curigliano, Vivek Subbiah, Philippe A Cassier, Salvatore Siena, Elena Garralda, Luis Paz-Ares, Pilar Garrido, Ernest Nadal, Jacqueline Vuky, Gilberto Lopes, Gregory P Kalemkerian, Daniel W Bowles, Mahesh Seetharam, Jianhua Chang, Hui Zhang, Jennifer Green, Alena Zalutskaya, Martin Schuler, Yun Fan, Giuseppe Curigliano
Abstract
Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of RET receptor tyrosine kinase. ARROW ( NCT03037385 , ongoing) was designed to evaluate pralsetinib efficacy and safety in patients with advanced RET-altered solid tumors. Twenty-nine patients with 12 different RET fusion-positive solid tumor types, excluding non-small-cell lung cancer and thyroid cancer, who had previously received or were not candidates for standard therapies, were enrolled. The most common RET fusion partners in 23 efficacy-evaluable patients were CCDC6 (26%), KIF5B (26%) and NCOA4 (13%). Overall response rate, the primary endpoint, was 57% (95% confidence interval, 35-77) among these patients. Responses were observed regardless of tumor type or RET fusion partner. Median duration of response, progression-free survival and overall survival were 12 months, 7 months and 14 months, respectively. The most common grade ≥3 treatment-related adverse events were neutropenia (31%) and anemia (14%). These data validate RET as a tissue-agnostic target with sensitivity to RET inhibition, indicating pralsetinib's potential as a well-tolerated treatment option with rapid, robust and durable anti-tumor activity in patients with diverse RET fusion-positive solid tumors.
Conflict of interest statement
V.S. reports research funding/grant support for clinical trials from AbbVie, Agensys, Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines, Boston Biomedical, Boston Pharmaceuticals, Celgene, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Incyte, Inhibrx, Loxo Oncology, MedImmune, MultiVir, NanoCarrier, National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics, MD Anderson Cancer Center and Vegenics; travel support from ASCO, ESMO, Helsinn Healthcare, Incyte, Novartis and PharmaMar; consultancy/advisory board participation for Helsinn Healthcare, Incyte, Loxo Oncology/Eli Lilly, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics, Daiichi-Sankyo, and R-Pharm US; and other relationship with Medscape. P.A.C. reports receiving honoraria from Amgen, Blueprint Medicines, Merck Serono, Merck Sharp & Dohme, Novartis, and Roche/Genentech; travel, accommodations and expenses from Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, NETRIS Pharma, Novartis and Roche; non-financial support from Merck Sharpe & Dohme, Novartis and Plexxikon; research funding from Novartis and Merck Sharpe & Dohme; and research funding to institution from AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Innate Pharma, Janssen Pharmaceuticals, Loxo Oncology, Merck Serono, Merck Sharp & Dohme, Novartis, Plexxikon, Roche/Genentech, Taiho Pharmaceutical, Toray Industries and Transgene. S.S. is an advisory board member for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Checkmab, Daiichi-Sankyo, Merck, Roche/Genentech and Seattle Genetics. E.G. reports personal fees from Alkermes, Bristol Myers Squibb, Boehringer Ingelheim, Ellipses Pharma, Genentech, F. Hoffmann-La Roche, Janssen Pharmaceuticals, Merck Sharpe & Dohme, Neomed Therapeutics, Seattle Genetics, TFS Health Science and Thermo Fisher Scientific; research funding from Novartis, Roche and Thermo Fisher Scientific; and travel grants from Glycotope and Menarini. L.P.A. reports personal fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, Eli Lilly, Merck, Merck Sharpe & Dohme, Ipsen, Mirati Therapeutics, Novartis, Pfizer, PharmaMar, Roche, Sanofi and Servier; grants from AstraZeneca, Bristol Myers Squibb, Merck Sharpe & Dohme and Pfizer; and other funding from Altum Sequencing and Genomica. P.G. reports a consulting or advisory role for AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Guardant Health, Janssen Pharmaceuticals, Novartis, Merck Sharpe & Dohme, Pfizer, Roche and Takeda; speakers bureau for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences, MSD Oncology, Novartis, Pfizer, ROVI, Roche and Takeda; travel, accommodations and expenses support from AstraZeneca, Bristol Myers Squibb and Roche; and research funding from Guardant Health and Sysmex. E.N. reports consulting or advisory role and lectures for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck-Serono, MSD Oncology, Pfizer, Roche and Takeda; and research funding from Bristol Myers Squibb, Merck-Serono, Pfizer and Roche. J.V. reports having consulted and/or having advisory roles for AstraZeneca, Bristol Myers Squibb and Seattle Genetics/Astellas; and institutional research funding from Agendia, Arvinas, Astellas Pharma, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Celldex, Clovis Oncology, Deciphera, Eisai, Exelixis, Fortis, Roche/Genetech, Ignyta, Incyte, Innocrin Pharma, Eli Lilly, Loxo, Merck, Novartis, Pfizer, Polyphor and Rgenix. G.L. reports having consulted and/or having advisory roles for AstraZeneca and Pfizer; received travel, accommodations and expenses from Boehringer Ingelheim, E.R. Squibb & Sons, Janssen Pharmaceuticals and Pfizer; received honoraria from Boehringer Ingelheim; received research funding from AstraZeneca; and received research funding to their institution from AbbVie, Adaptimmune Therapeutics, AstraZeneca, Bavarian Nordic, Blueprint Medicines, Bristol Myers Squibb, Eli Lilly, EMD Serono, G1 Therapeutics, GlaxoSmithKline, Janssen Pharmaceuticals, Merck Sharpe & Dohme, Novartis, Pfizer, Rgenix, Roche/Genentech and Tesaro. G.P.K. received research funding/grant support for clinical trials from AbbVie, Blueprint Medicines, Daiichi, Merck, Cullinan and Takeda. D.W.B. declares no conflicts of interest. M. Seetharam. reports having consulted and/or having an advisory role for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, MorphoSys, Novartis, Roche and Takeda; and received honoraria from Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharpe & Dohme and Novartis; and institutional research funding from AstraZeneca and Bristol Myers Squibb. J.C. declares no conflicts of interest. H.Z. is an employee and shareholder of Blueprint Medicines. J.G. reports having a consulting or advisory role with Arvinas, Blueprint Medicines, Genocea Biosciences and Tesaro. A.Z. is an employee and shareholder of Blueprint Medicines. M. Schuler. reports having a consulting or advisory role for Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Roche, Sanofi and Takeda; having received honoraria from Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Merck Serono, Novartis and Roche; having received research funding to his institution from AstraZeneca and Bristol Myers Squibb; and his institution has patents, royalties and other intellectual property of a highly sensitive method for mutation detection by PCR. Y.F. received honoraria as a speaker from AstraZeneca, Bristol Myers Squibb, CStone, Hengrui, Innovent Biologics, Lilly China, Roche, Merck Sharpe & Dohme, Novartis and Pfizer. G.C. reports having a consulting or advisory role for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Eli Lilly, Foundation Medicine, GlaxoSmithKline, Novartis, Pfizer, Roche/Genentech, Samsung, Exact Sciences, Merck and Seagent; having served on speakers bureau for Daiichi-Sankyo, Eli Lilly, Foundation Medicine, Novartis, Pfizer, Roche/Genentech and Samsung; having received travel, accommodations and expenses support from Roche/Genentech, Daichii-Sankyo and Pfizer; having received honoraria from Ellipses Pharma; and having received research funding from Merck.
© 2022. The Author(s).
Figures
References
- Drilon A, et al. Efficacy of selpercatinib in RET fusion-positive non-small cell lung cancer. N. Engl. J. Med. 2020;383:813–824. doi: 10.1056/NEJMoa2005653.
- Subbiah V, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8:836–849. doi: 10.1158/-18-0338.
- Subbiah V, Cote GJ. Advances in targeting RET-dependent cancers. Cancer Discov. 2020;10:498–505. doi: 10.1158/-19-1116.
- Kato S, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin. Cancer Res. 2017;23:1988–1997. doi: 10.1158/1078-0432.CCR-16-1679.
- Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007;148:936–941. doi: 10.1210/en.2006-0921.
- Kohno T, et al. KIF5B–RET fusions in lung adenocarcinoma. Nat. Med. 2012;18:375–377. doi: 10.1038/nm.2644.
- Lipson D, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 2012;18:382–384. doi: 10.1038/nm.2673.
- Le Rolle AF, et al. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget. 2015;6:28929–28937. doi: 10.18632/oncotarget.4325.
- Subbiah, V. et al. Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 stidy of advanced, RET-altered solid tumors. Cancer Res.78, CTO43 (2018).
- Gainor JF, et al. Pralsetinib for RET fusion–positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22:959–969. doi: 10.1016/S1470-2045(21)00247-3.
- Subbiah V, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9:491–501. doi: 10.1016/S2213-8587(21)00120-0.
- Blueprint Medicines. GAVRETO (pralsetinib). Prescribing information. (2020).
- Roche Registration. GAVRETO (pralsetinib). Summary of product characteristics. (2021).
- Looney AM, Nawaz K, Webster RM. Tumour-agnostic therapies. Nat. Rev. Drug Discov. 2020;19:383–384. doi: 10.1038/d41573-020-00015-1.
- Genentech USA. ROZLYTREK (entrectinib) capsules. Prescribing information. (2019).
- Bayer Healthcare Pharmaceuticals. VITRAKVI (larotrectinib). Prescribing information. (2020).
- Merck Sharpe & Dohme. KEYTRUDA (pembrolizumab) injection. Prescribing information. (2019).
- GlaxoSmithKline. JEMPERLI (dostarlimab-gxly). Prescribing information. (2021).
- Eli Lilly USA. RETEVMO (selpercatinib) prescribing information. (2020).
- National Comprehensive Cancer Network (NCCN). Non-Small Cell Lung Cancer (version 7). (2021).
- National Comprehensive Cancer Network (NCCN). Thyroid Carcinoma (version 1.2021). (2021).
- Filetti S, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019;30:1856–1883. doi: 10.1093/annonc/mdz400.
- European Society for Medical Oncology. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020).
- Planchard D, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018;29:iv192–iv237. doi: 10.1093/annonc/mdy275.
- Paratala BS, et al. RET rearrangements are actionable alterations in breast cancer. Nat. Commun. 2018;9:4821. doi: 10.1038/s41467-018-07341-4.
- Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010;362:2380–2388. doi: 10.1056/NEJMoa0909530.
- Peters S, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 2017;377:829–838. doi: 10.1056/NEJMoa1704795.
- Soria J-C, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 2018;378:113–125. doi: 10.1056/NEJMoa1713137.
- Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 2010;362:1273–1281. doi: 10.1056/NEJMoa0908721.
- Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011;364:1817–1825. doi: 10.1056/NEJMoa1011923.
- Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013;369:1691–1703. doi: 10.1056/NEJMoa1304369.
- Subbiah, V. et al. Efficacy and safety of selpercatinib in RET fusion–positive cancers other than lung or thyroid cancers. Annual Meeting of the American Association for Cancer Research. (2021).
Source: PubMed